Herminia Diana Rosas, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Huntington Disease | 48 | 2024 | 1147 | 7.490 |
Why?
|
| Down Syndrome | 14 | 2024 | 919 | 1.600 |
Why?
|
| Nerve Fibers, Myelinated | 8 | 2018 | 952 | 1.230 |
Why?
|
| Corpus Callosum | 5 | 2024 | 752 | 0.970 |
Why?
|
| Alzheimer Disease | 20 | 2024 | 8759 | 0.880 |
Why?
|
| Brain | 30 | 2024 | 27362 | 0.800 |
Why?
|
| Putamen | 2 | 2020 | 291 | 0.800 |
Why?
|
| Nerve Degeneration | 5 | 2018 | 749 | 0.780 |
Why?
|
| Creatine | 4 | 2017 | 427 | 0.780 |
Why?
|
| Cerebral Cortex | 11 | 2023 | 5812 | 0.740 |
Why?
|
| Myelin Sheath | 2 | 2018 | 652 | 0.690 |
Why?
|
| Parahippocampal Gyrus | 3 | 2016 | 118 | 0.690 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 8 | 2018 | 2815 | 0.550 |
Why?
|
| Trinucleotide Repeats | 7 | 2012 | 257 | 0.550 |
Why?
|
| tau Proteins | 9 | 2024 | 2144 | 0.530 |
Why?
|
| Neostriatum | 1 | 2016 | 236 | 0.490 |
Why?
|
| Magnetic Resonance Imaging | 25 | 2024 | 36741 | 0.470 |
Why?
|
| Atrophy | 11 | 2014 | 1646 | 0.420 |
Why?
|
| Pattern Recognition, Visual | 1 | 2019 | 826 | 0.410 |
Why?
|
| Diffusion Tensor Imaging | 10 | 2024 | 2420 | 0.410 |
Why?
|
| Visual Pathways | 1 | 2016 | 557 | 0.400 |
Why?
|
| Amyloid beta-Peptides | 10 | 2024 | 3914 | 0.380 |
Why?
|
| Neuroprotective Agents | 3 | 2017 | 958 | 0.380 |
Why?
|
| Neural Pathways | 6 | 2024 | 3117 | 0.370 |
Why?
|
| Cerebrovascular Disorders | 3 | 2024 | 1485 | 0.370 |
Why?
|
| Visual Cortex | 3 | 2016 | 1094 | 0.360 |
Why?
|
| Axons | 2 | 2018 | 1677 | 0.350 |
Why?
|
| Cognition Disorders | 6 | 2014 | 3980 | 0.320 |
Why?
|
| Hippocampus | 4 | 2016 | 3783 | 0.310 |
Why?
|
| Limbic System | 1 | 2010 | 424 | 0.300 |
Why?
|
| Positron-Emission Tomography | 9 | 2024 | 6669 | 0.290 |
Why?
|
| Aging | 9 | 2024 | 8743 | 0.280 |
Why?
|
| Cerebrovascular Circulation | 3 | 2013 | 2725 | 0.280 |
Why?
|
| Middle Aged | 55 | 2024 | 223487 | 0.280 |
Why?
|
| Chromosomes, Human, Pair 4 | 2 | 2012 | 378 | 0.270 |
Why?
|
| Adult | 55 | 2024 | 223646 | 0.260 |
Why?
|
| Deoxyguanosine | 1 | 2006 | 96 | 0.250 |
Why?
|
| Female | 66 | 2024 | 397187 | 0.240 |
Why?
|
| Neurologic Examination | 3 | 2009 | 914 | 0.240 |
Why?
|
| Male | 64 | 2024 | 364731 | 0.240 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2011 | 1429 | 0.240 |
Why?
|
| Fluorescence Resonance Energy Transfer | 3 | 2013 | 414 | 0.240 |
Why?
|
| Image Processing, Computer-Assisted | 7 | 2016 | 9016 | 0.230 |
Why?
|
| Brain Mapping | 9 | 2019 | 6684 | 0.220 |
Why?
|
| Iron | 1 | 2012 | 1813 | 0.220 |
Why?
|
| Amyloid | 3 | 2024 | 853 | 0.220 |
Why?
|
| Humans | 90 | 2024 | 768171 | 0.210 |
Why?
|
| Temporal Lobe | 1 | 2010 | 1726 | 0.210 |
Why?
|
| Trinucleotide Repeat Expansion | 4 | 2013 | 254 | 0.210 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2024 | 563 | 0.200 |
Why?
|
| Disease Progression | 10 | 2018 | 13668 | 0.190 |
Why?
|
| Age of Onset | 9 | 2023 | 3346 | 0.190 |
Why?
|
| Mosaicism | 1 | 2024 | 480 | 0.180 |
Why?
|
| Observation | 2 | 2013 | 310 | 0.180 |
Why?
|
| Image Interpretation, Computer-Assisted | 4 | 2020 | 3390 | 0.180 |
Why?
|
| Corpus Striatum | 3 | 2005 | 1224 | 0.170 |
Why?
|
| Choice Behavior | 1 | 2005 | 848 | 0.160 |
Why?
|
| Infarction | 1 | 2020 | 247 | 0.160 |
Why?
|
| Nerve Tissue Proteins | 6 | 2013 | 4413 | 0.160 |
Why?
|
| Riluzole | 1 | 1999 | 61 | 0.160 |
Why?
|
| Facial Expression | 1 | 2023 | 515 | 0.160 |
Why?
|
| Reaction Time | 1 | 2005 | 2101 | 0.160 |
Why?
|
| Hypertrophy | 1 | 2020 | 562 | 0.160 |
Why?
|
| Apolipoprotein E4 | 1 | 2023 | 712 | 0.150 |
Why?
|
| Mutant Proteins | 2 | 2010 | 488 | 0.150 |
Why?
|
| Thalamic Nuclei | 1 | 2018 | 110 | 0.150 |
Why?
|
| Single-Blind Method | 2 | 2018 | 1587 | 0.140 |
Why?
|
| Aged | 32 | 2024 | 171502 | 0.140 |
Why?
|
| Neuropsychological Tests | 7 | 2016 | 7140 | 0.140 |
Why?
|
| Rotation | 1 | 2019 | 517 | 0.140 |
Why?
|
| Anisotropy | 4 | 2010 | 1292 | 0.140 |
Why?
|
| Globus Pallidus | 1 | 2018 | 248 | 0.140 |
Why?
|
| Carbon Radioisotopes | 1 | 2018 | 567 | 0.140 |
Why?
|
| Neurodegenerative Diseases | 3 | 2022 | 1094 | 0.130 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 1999 | 451 | 0.130 |
Why?
|
| Acetamides | 1 | 2018 | 259 | 0.130 |
Why?
|
| Receptors, GABA | 1 | 2018 | 312 | 0.130 |
Why?
|
| Cross-Sectional Studies | 11 | 2024 | 26379 | 0.130 |
Why?
|
| Organ Size | 3 | 2010 | 2267 | 0.130 |
Why?
|
| Form Perception | 1 | 2016 | 175 | 0.120 |
Why?
|
| Ubiquinone | 1 | 2016 | 183 | 0.120 |
Why?
|
| Case-Control Studies | 9 | 2018 | 22290 | 0.120 |
Why?
|
| Motion Perception | 1 | 2019 | 379 | 0.120 |
Why?
|
| Attention | 1 | 2005 | 2423 | 0.120 |
Why?
|
| Double-Blind Method | 7 | 2017 | 12466 | 0.110 |
Why?
|
| rho-Associated Kinases | 1 | 2015 | 290 | 0.110 |
Why?
|
| Electrochemistry | 1 | 2013 | 145 | 0.100 |
Why?
|
| Severity of Illness Index | 5 | 2020 | 15949 | 0.100 |
Why?
|
| Receptors, Dopamine | 1 | 2013 | 293 | 0.100 |
Why?
|
| Receptors, Kainic Acid | 1 | 2012 | 91 | 0.100 |
Why?
|
| Polymorphism, Genetic | 3 | 2013 | 4249 | 0.100 |
Why?
|
| Codon, Terminator | 1 | 2012 | 125 | 0.100 |
Why?
|
| Radiography, Abdominal | 1 | 2015 | 541 | 0.100 |
Why?
|
| Guanine | 1 | 2013 | 280 | 0.100 |
Why?
|
| Frontal Lobe | 4 | 2015 | 1426 | 0.090 |
Why?
|
| Reproducibility of Results | 5 | 2015 | 20225 | 0.090 |
Why?
|
| Nuclear Proteins | 4 | 2010 | 5804 | 0.090 |
Why?
|
| Disease | 1 | 2016 | 675 | 0.090 |
Why?
|
| Peptide Fragments | 2 | 2021 | 5151 | 0.090 |
Why?
|
| Emotions | 1 | 2023 | 2767 | 0.090 |
Why?
|
| Psychomotor Performance | 3 | 2010 | 1892 | 0.090 |
Why?
|
| Creatine Kinase, BB Form | 1 | 2010 | 7 | 0.090 |
Why?
|
| Face | 1 | 2016 | 1031 | 0.090 |
Why?
|
| Astrocytes | 1 | 2018 | 1350 | 0.090 |
Why?
|
| Basal Ganglia | 2 | 2006 | 553 | 0.090 |
Why?
|
| Young Adult | 10 | 2020 | 60066 | 0.090 |
Why?
|
| Leukoencephalopathies | 1 | 2013 | 259 | 0.080 |
Why?
|
| Nerve Fibers, Unmyelinated | 1 | 2010 | 98 | 0.080 |
Why?
|
| Imaging, Three-Dimensional | 3 | 2016 | 4064 | 0.080 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2013 | 1535 | 0.080 |
Why?
|
| Microglia | 1 | 2018 | 1376 | 0.080 |
Why?
|
| Leukocytes | 2 | 2015 | 2034 | 0.080 |
Why?
|
| Postmortem Changes | 3 | 2015 | 119 | 0.080 |
Why?
|
| Cross-Over Studies | 2 | 2014 | 2107 | 0.080 |
Why?
|
| Entorhinal Cortex | 1 | 2010 | 287 | 0.080 |
Why?
|
| Longitudinal Studies | 6 | 2021 | 14783 | 0.080 |
Why?
|
| Amygdala | 1 | 2016 | 1379 | 0.080 |
Why?
|
| Heat-Shock Proteins | 1 | 2012 | 797 | 0.080 |
Why?
|
| Neurofilament Proteins | 2 | 2021 | 336 | 0.080 |
Why?
|
| Internal Capsule | 2 | 2006 | 138 | 0.080 |
Why?
|
| Hemorrhage | 1 | 2020 | 3466 | 0.080 |
Why?
|
| Vitamins | 1 | 2016 | 1638 | 0.080 |
Why?
|
| Parkinson Disease | 1 | 2022 | 2893 | 0.080 |
Why?
|
| Radiopharmaceuticals | 1 | 2018 | 2735 | 0.070 |
Why?
|
| Visual Perception | 1 | 2016 | 1401 | 0.070 |
Why?
|
| Thymidine | 1 | 1988 | 297 | 0.070 |
Why?
|
| Time Factors | 4 | 2018 | 40220 | 0.070 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2013 | 903 | 0.070 |
Why?
|
| Blood Flow Velocity | 1 | 2011 | 1375 | 0.070 |
Why?
|
| Retroviridae Infections | 1 | 1988 | 148 | 0.070 |
Why?
|
| Aged, 80 and over | 12 | 2016 | 59626 | 0.070 |
Why?
|
| Extrapyramidal Tracts | 1 | 2006 | 17 | 0.070 |
Why?
|
| Sleep | 1 | 2023 | 4818 | 0.070 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2013 | 1854 | 0.070 |
Why?
|
| Rett Syndrome | 1 | 2008 | 164 | 0.070 |
Why?
|
| Valine | 1 | 2008 | 410 | 0.070 |
Why?
|
| Apolipoproteins E | 2 | 2023 | 1461 | 0.070 |
Why?
|
| Pyridines | 1 | 2018 | 2894 | 0.070 |
Why?
|
| Memory Disorders | 2 | 2004 | 1200 | 0.060 |
Why?
|
| Mice, Transgenic | 5 | 2023 | 9561 | 0.060 |
Why?
|
| Lumbar Vertebrae | 1 | 2015 | 1886 | 0.060 |
Why?
|
| Methionine | 1 | 2008 | 573 | 0.060 |
Why?
|
| Mice, Inbred CBA | 3 | 2011 | 439 | 0.060 |
Why?
|
| Osteoporosis | 1 | 2015 | 1605 | 0.060 |
Why?
|
| Early Diagnosis | 2 | 2009 | 1194 | 0.060 |
Why?
|
| Hand | 1 | 2010 | 913 | 0.060 |
Why?
|
| Biological Availability | 1 | 2006 | 391 | 0.060 |
Why?
|
| Genetic Counseling | 1 | 2009 | 635 | 0.060 |
Why?
|
| Statistics as Topic | 1 | 2011 | 2357 | 0.060 |
Why?
|
| Encephalitis | 2 | 2021 | 441 | 0.060 |
Why?
|
| Pyramidal Tracts | 1 | 2006 | 251 | 0.060 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2008 | 605 | 0.060 |
Why?
|
| Dementia | 3 | 2008 | 2740 | 0.060 |
Why?
|
| Interferon Type I | 1 | 1988 | 569 | 0.060 |
Why?
|
| Insulin Resistance | 2 | 2016 | 3986 | 0.060 |
Why?
|
| Prefrontal Cortex | 2 | 2023 | 2238 | 0.050 |
Why?
|
| Quality of Life | 2 | 2023 | 13490 | 0.050 |
Why?
|
| Australia | 2 | 2017 | 1265 | 0.050 |
Why?
|
| Lactic Acid | 2 | 1999 | 1140 | 0.050 |
Why?
|
| Models, Neurological | 2 | 2008 | 1776 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2012 | 16044 | 0.050 |
Why?
|
| Central Nervous System | 1 | 2010 | 1346 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2014 | 5315 | 0.050 |
Why?
|
| Antibodies | 1 | 2010 | 2421 | 0.050 |
Why?
|
| Genotype | 3 | 2021 | 13045 | 0.050 |
Why?
|
| Telomere | 1 | 2008 | 943 | 0.050 |
Why?
|
| Parietal Lobe | 1 | 2006 | 866 | 0.050 |
Why?
|
| Histones | 1 | 2011 | 2601 | 0.050 |
Why?
|
| Time | 1 | 2023 | 552 | 0.050 |
Why?
|
| Motor Activity | 1 | 2010 | 2711 | 0.040 |
Why?
|
| Gliosis | 1 | 2021 | 246 | 0.040 |
Why?
|
| Cohort Studies | 4 | 2018 | 41753 | 0.040 |
Why?
|
| Alleles | 4 | 2012 | 6894 | 0.040 |
Why?
|
| Magnetic Resonance Spectroscopy | 3 | 1999 | 3782 | 0.040 |
Why?
|
| Genetic Markers | 1 | 2005 | 2603 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2011 | 14729 | 0.040 |
Why?
|
| Serine | 1 | 2023 | 831 | 0.040 |
Why?
|
| Predictive Value of Tests | 4 | 2009 | 15453 | 0.040 |
Why?
|
| Sex Characteristics | 1 | 2009 | 2649 | 0.040 |
Why?
|
| Nervous System Diseases | 3 | 2013 | 1662 | 0.040 |
Why?
|
| Functional Laterality | 1 | 2005 | 2264 | 0.040 |
Why?
|
| Cerebral Amyloid Angiopathy | 1 | 2006 | 887 | 0.040 |
Why?
|
| DNA Methylation | 1 | 2013 | 4428 | 0.040 |
Why?
|
| Chorea | 1 | 1999 | 80 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2005 | 2732 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2010 | 3573 | 0.040 |
Why?
|
| Inflammation | 1 | 2018 | 10873 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 1988 | 6512 | 0.040 |
Why?
|
| Family | 1 | 2009 | 3209 | 0.040 |
Why?
|
| Algorithms | 3 | 2015 | 14164 | 0.040 |
Why?
|
| Treatment Outcome | 5 | 2017 | 65379 | 0.040 |
Why?
|
| Occipital Lobe | 1 | 1999 | 376 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2005 | 4120 | 0.030 |
Why?
|
| New Zealand | 1 | 2017 | 360 | 0.030 |
Why?
|
| Genetic Testing | 2 | 2009 | 3591 | 0.030 |
Why?
|
| Encephalocele | 1 | 1997 | 135 | 0.030 |
Why?
|
| Lead Poisoning | 1 | 1998 | 323 | 0.030 |
Why?
|
| Dominance, Cerebral | 1 | 1997 | 623 | 0.030 |
Why?
|
| Staphylococcal Protein A | 1 | 1995 | 39 | 0.030 |
Why?
|
| Actin Depolymerizing Factors | 1 | 2015 | 42 | 0.030 |
Why?
|
| Profilins | 1 | 2015 | 65 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 1988 | 3072 | 0.030 |
Why?
|
| Immunosorbent Techniques | 1 | 1995 | 174 | 0.030 |
Why?
|
| Mental Status Schedule | 1 | 2016 | 315 | 0.030 |
Why?
|
| Seizures | 1 | 2008 | 2998 | 0.030 |
Why?
|
| Myoclonus | 1 | 1995 | 107 | 0.030 |
Why?
|
| Heterozygote | 1 | 2021 | 2798 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2014 | 18065 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2016 | 684 | 0.030 |
Why?
|
| Histone Deacetylase Inhibitors | 2 | 2011 | 778 | 0.030 |
Why?
|
| Disease Models, Animal | 3 | 2023 | 18349 | 0.030 |
Why?
|
| North America | 1 | 2017 | 1289 | 0.030 |
Why?
|
| Ocular Motility Disorders | 1 | 1995 | 144 | 0.030 |
Why?
|
| Paraneoplastic Syndromes | 1 | 1995 | 154 | 0.030 |
Why?
|
| Femur Neck | 1 | 2015 | 318 | 0.030 |
Why?
|
| Lipoproteins, LDL | 1 | 2016 | 644 | 0.030 |
Why?
|
| Age Factors | 2 | 2024 | 18415 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 4 | 2015 | 22380 | 0.030 |
Why?
|
| Phenotype | 2 | 2008 | 16726 | 0.030 |
Why?
|
| Factor Analysis, Statistical | 1 | 2016 | 1001 | 0.030 |
Why?
|
| Cerebellar Diseases | 1 | 1995 | 227 | 0.030 |
Why?
|
| Brain Edema | 1 | 1997 | 601 | 0.030 |
Why?
|
| Craniotomy | 1 | 1997 | 736 | 0.030 |
Why?
|
| Receptors, Dopamine D4 | 1 | 2013 | 168 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2012 | 12171 | 0.030 |
Why?
|
| Nerve Fibers | 1 | 2016 | 709 | 0.030 |
Why?
|
| Animals | 10 | 2023 | 169285 | 0.030 |
Why?
|
| Massachusetts | 1 | 2005 | 8890 | 0.030 |
Why?
|
| Cerebral Infarction | 1 | 1997 | 969 | 0.020 |
Why?
|
| Learning | 1 | 2001 | 1759 | 0.020 |
Why?
|
| Mice | 6 | 2023 | 82049 | 0.020 |
Why?
|
| Decompression, Surgical | 1 | 1997 | 603 | 0.020 |
Why?
|
| Memory | 1 | 2001 | 2207 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2015 | 23648 | 0.020 |
Why?
|
| Proteome | 1 | 2022 | 1890 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2023 | 8316 | 0.020 |
Why?
|
| Founder Effect | 1 | 2012 | 185 | 0.020 |
Why?
|
| Canada | 1 | 2016 | 2130 | 0.020 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2013 | 251 | 0.020 |
Why?
|
| Weight Loss | 1 | 2023 | 2721 | 0.020 |
Why?
|
| Pilot Projects | 2 | 2008 | 8741 | 0.020 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 2013 | 417 | 0.020 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2013 | 471 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2015 | 2230 | 0.020 |
Why?
|
| Incidental Findings | 1 | 2015 | 698 | 0.020 |
Why?
|
| Calibration | 1 | 2013 | 819 | 0.020 |
Why?
|
| Energy Metabolism | 2 | 1999 | 2907 | 0.020 |
Why?
|
| International Cooperation | 1 | 2016 | 1436 | 0.020 |
Why?
|
| 3' Untranslated Regions | 1 | 2012 | 515 | 0.020 |
Why?
|
| Organic Chemicals | 1 | 2010 | 211 | 0.020 |
Why?
|
| Follow-Up Studies | 3 | 2017 | 39354 | 0.020 |
Why?
|
| Venezuela | 1 | 2009 | 73 | 0.020 |
Why?
|
| Absorptiometry, Photon | 1 | 2015 | 1758 | 0.020 |
Why?
|
| Femur | 1 | 2015 | 1321 | 0.020 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 2010 | 781 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2013 | 1505 | 0.020 |
Why?
|
| Adolescent | 6 | 2020 | 89169 | 0.020 |
Why?
|
| Proteomics | 1 | 2022 | 3912 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2024 | 4754 | 0.020 |
Why?
|
| Gene Expression | 2 | 2011 | 7601 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2015 | 5028 | 0.020 |
Why?
|
| Genetics, Population | 1 | 2012 | 944 | 0.020 |
Why?
|
| Penetrance | 1 | 2009 | 385 | 0.020 |
Why?
|
| Child | 6 | 2020 | 80917 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2024 | 9262 | 0.020 |
Why?
|
| DNA | 2 | 2010 | 7213 | 0.020 |
Why?
|
| Cell Count | 1 | 2010 | 1832 | 0.020 |
Why?
|
| Methyl-CpG-Binding Protein 2 | 1 | 2008 | 183 | 0.020 |
Why?
|
| Macaca | 1 | 2008 | 413 | 0.020 |
Why?
|
| Research Design | 1 | 2022 | 6209 | 0.020 |
Why?
|
| Cell Line | 2 | 2010 | 15602 | 0.020 |
Why?
|
| Zidovudine | 1 | 1988 | 625 | 0.020 |
Why?
|
| Haplotypes | 1 | 2012 | 2722 | 0.020 |
Why?
|
| Child, Preschool | 3 | 2020 | 42669 | 0.020 |
Why?
|
| Neocortex | 1 | 2009 | 416 | 0.020 |
Why?
|
| Europe | 1 | 2012 | 3436 | 0.020 |
Why?
|
| Phenylbutyrates | 1 | 2005 | 72 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2013 | 2885 | 0.010 |
Why?
|
| Plaque, Amyloid | 1 | 2008 | 769 | 0.010 |
Why?
|
| RNA, Messenger | 2 | 2011 | 12801 | 0.010 |
Why?
|
| Drug Synergism | 1 | 1988 | 1760 | 0.010 |
Why?
|
| Genetic Association Studies | 1 | 2013 | 2744 | 0.010 |
Why?
|
| Species Specificity | 1 | 2008 | 2415 | 0.010 |
Why?
|
| Exons | 1 | 2009 | 2394 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2010 | 2939 | 0.010 |
Why?
|
| United States | 2 | 2024 | 73039 | 0.010 |
Why?
|
| Probability | 1 | 2008 | 2479 | 0.010 |
Why?
|
| Hemodynamics | 1 | 2013 | 4194 | 0.010 |
Why?
|
| Embryonic Stem Cells | 1 | 2009 | 1250 | 0.010 |
Why?
|
| Bone Density | 1 | 2015 | 3573 | 0.010 |
Why?
|
| Reference Values | 1 | 2009 | 4939 | 0.010 |
Why?
|
| Contrast Media | 1 | 2015 | 5330 | 0.010 |
Why?
|
| Retrospective Studies | 3 | 2016 | 81760 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 12543 | 0.010 |
Why?
|
| Radiography | 1 | 2013 | 6986 | 0.010 |
Why?
|
| Insulin | 1 | 2016 | 6610 | 0.010 |
Why?
|
| Scopolamine | 1 | 2001 | 93 | 0.010 |
Why?
|
| Muscarinic Antagonists | 1 | 2001 | 136 | 0.010 |
Why?
|
| Lorazepam | 1 | 2001 | 155 | 0.010 |
Why?
|
| DNA Primers | 1 | 2005 | 2828 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2016 | 8543 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2009 | 6229 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2009 | 3740 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2010 | 4178 | 0.010 |
Why?
|
| Mass Screening | 1 | 2015 | 5458 | 0.010 |
Why?
|
| Anti-Anxiety Agents | 1 | 2001 | 405 | 0.010 |
Why?
|
| Ecuador | 1 | 1998 | 62 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 1988 | 6231 | 0.010 |
Why?
|
| Brain Diseases | 1 | 2008 | 1554 | 0.010 |
Why?
|
| Mutation | 2 | 2013 | 30237 | 0.010 |
Why?
|
| Ceramics | 1 | 1998 | 113 | 0.010 |
Why?
|
| Infant | 1 | 2020 | 36535 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 1988 | 6316 | 0.010 |
Why?
|
| Placebos | 1 | 2001 | 1667 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 8052 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2015 | 11930 | 0.010 |
Why?
|
| Risk Factors | 1 | 2024 | 74944 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2005 | 3806 | 0.010 |
Why?
|
| Oxidative Phosphorylation | 1 | 1999 | 501 | 0.010 |
Why?
|
| Industry | 1 | 1998 | 362 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2008 | 17623 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1988 | 10763 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2005 | 3728 | 0.010 |
Why?
|
| Cerebral Hemorrhage | 1 | 2006 | 2654 | 0.010 |
Why?
|
| Base Sequence | 1 | 2005 | 12422 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2009 | 4978 | 0.010 |
Why?
|
| Logistic Models | 1 | 2008 | 13290 | 0.010 |
Why?
|
| Protons | 1 | 1998 | 1113 | 0.010 |
Why?
|
| Lead | 1 | 1998 | 882 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2012 | 12795 | 0.010 |
Why?
|
| Genome, Human | 1 | 2005 | 4446 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 20762 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2005 | 13013 | 0.010 |
Why?
|
| Neurons | 1 | 2009 | 9514 | 0.010 |
Why?
|
| Disability Evaluation | 1 | 1997 | 1835 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2005 | 9540 | 0.010 |
Why?
|
| Occupational Exposure | 1 | 1998 | 1807 | 0.000 |
Why?
|
| Linear Models | 1 | 1998 | 5884 | 0.000 |
Why?
|
| Activities of Daily Living | 1 | 1997 | 2430 | 0.000 |
Why?
|
| Oxidative Stress | 1 | 1999 | 3140 | 0.000 |
Why?
|
| Cause of Death | 1 | 1997 | 3721 | 0.000 |
Why?
|
| Environmental Exposure | 1 | 1998 | 4543 | 0.000 |
Why?
|
| Survival Rate | 1 | 1997 | 12840 | 0.000 |
Why?
|
| Postoperative Complications | 1 | 1997 | 15833 | 0.000 |
Why?
|
| Prospective Studies | 1 | 1997 | 54924 | 0.000 |
Why?
|